SRX Global

SRXH

Börsenwert 24,1 Mio. $

New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next generation of proprietary traders under Eric Jackson's leadership New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next generation of proprietary traders under Eric Jackson's leadership

SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has entered into definitive purchase agreement under which CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo Holdings" and, together with CERo Therapeutics, "CERo"), an innovative cellular immunotherapy company advancing the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, will become a wholly owned subsidiary of SRX Global.

SRX to dividend ETF holdings to shareholders  Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX's proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced a $1.5 million commitment to launch a new family of actively managed Exchange Traded Funds (ETFs) through its EMJX platform, marking the first step in bringing EMJX's proprietary AI-driven investment intelligence to the broader investing public.

SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras. SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.

NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that SRX Global's CEO, Kent Cunningham, and President, EMJX Platform and Head of Asset Management, Eric Jackson, will present at the Webull Corporate Connect Series Fintech Investment Webinar, a live investor webinar hosted on the Webull platform, on September 30, 2026.

NORTH PALM BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today is providing shareholders with an update on its portfolio company ARMR Sciences (“ARMR”), a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl, from its CEO, Collin Gage.

The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers

Net Asset Value ("NAV") of  $62.9 million , or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricted Cash, $65.2 million in Current Assets, and $2.4 million in Total Liabilities, With No Debt Outstanding Adjusted EBITDA Loss Improved 35% year over year to $1.6 million 4 Strengthened Halo Operations, Exiting the Quarter with 98% Fill Rates and Record Prime Day Performance NORTH PALM BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced its financial results for the fiscal third quarter ended June 30, 2026.

NORTH PALM BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it plans to host a conference call and report its financial results for the fiscal third quarter ended June 30, 2026, on Thursday, August 13, 2026.

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines.